Biotech Values

[iwfal]

CLDX -

I noticed that the CEO stated that "patients with >25% GPNMB expression levels and patients with triple negative disease account for more than 35% of the total breast cancer population..." I believe that number is considerably higher than someone--possibly Peter or jq--had said in a post directed to me some time ago.

It is true that the BC patients who are Triple Negative and/or High G do make up more than 35%. However, as I pointed out earlier, the ph ii data they just released makes it clear that the group matters in Triple Negative AND High G. There is little or no efficacy with this protocol in HG by itself or TN by itself. And patients who are TN AND High G appears to be make up 10% of the BC population (at least as seen in the trial).